NZ629204A - Anti-vla1 (cd49a) antibody pharmaceutical compositions - Google Patents

Anti-vla1 (cd49a) antibody pharmaceutical compositions

Info

Publication number
NZ629204A
NZ629204A NZ629204A NZ62920413A NZ629204A NZ 629204 A NZ629204 A NZ 629204A NZ 629204 A NZ629204 A NZ 629204A NZ 62920413 A NZ62920413 A NZ 62920413A NZ 629204 A NZ629204 A NZ 629204A
Authority
NZ
New Zealand
Prior art keywords
vla1
cd49a
pharmaceutical compositions
antibody
antibody pharmaceutical
Prior art date
Application number
NZ629204A
Other languages
English (en)
Inventor
Adam Jeremy Fowler
Craig Michael Bowe
Wayne Curtis Yount
Nathan Jeremy Cobb
Timothy Martin Kelly
Original Assignee
Santarus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santarus Inc filed Critical Santarus Inc
Publication of NZ629204A publication Critical patent/NZ629204A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ629204A 2012-02-16 2013-02-14 Anti-vla1 (cd49a) antibody pharmaceutical compositions NZ629204A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261599827P 2012-02-16 2012-02-16
PCT/US2013/026034 WO2013123114A2 (en) 2012-02-16 2013-02-14 Antibody formulations

Publications (1)

Publication Number Publication Date
NZ629204A true NZ629204A (en) 2016-09-30

Family

ID=47997774

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629204A NZ629204A (en) 2012-02-16 2013-02-14 Anti-vla1 (cd49a) antibody pharmaceutical compositions

Country Status (11)

Country Link
US (5) US10316095B2 (OSRAM)
EP (1) EP2814468B1 (OSRAM)
JP (2) JP6345123B2 (OSRAM)
CN (1) CN104271122A (OSRAM)
AU (2) AU2013221635B2 (OSRAM)
CA (1) CA2864539C (OSRAM)
ES (1) ES2732243T3 (OSRAM)
IL (1) IL233976B (OSRAM)
MX (1) MX370199B (OSRAM)
NZ (1) NZ629204A (OSRAM)
WO (1) WO2013123114A2 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4817503B2 (ja) 1999-06-01 2011-11-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
EE200300509A (et) 2001-04-13 2004-08-16 Biogen, Inc. Antikehad VLA-1 vastu
PL2521568T3 (pl) 2010-01-06 2019-03-29 Dyax Corp. Białka wiążące kalikreinę osocza
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
CA2906624A1 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
JP6845012B2 (ja) 2014-01-21 2021-03-17 ダイアックス コーポレーション 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
EP3116911B8 (en) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
KR20230109785A (ko) 2014-03-27 2023-07-20 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
CN107106488A (zh) * 2014-09-29 2017-08-29 库克通用生物技术有限责任公司 海藻糖在细胞混悬液中的用途
WO2016054259A1 (en) 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US20160367180A1 (en) * 2015-06-17 2016-12-22 Obsevera, Inc. Apparatus and method of conducting medical evaluation of add/adhd
EP3350226A2 (en) * 2015-09-16 2018-07-25 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112018068628A2 (pt) * 2016-03-14 2019-07-30 Millennium Pharm Inc método de prevenção de doença do enxerto contra hospedeiro
AU2017286375B2 (en) * 2016-06-16 2019-04-18 Janssen Vaccines & Prevention B.V. HIV vaccine formulation
TN2018000443A1 (en) * 2016-06-30 2020-06-15 Celltrion Inc Stable liquid pharmaceutical preparation
EP3655011A4 (en) 2017-07-20 2021-03-31 University Of Virginia Patent Foundation PROCEDURES FOR THE TREATMENT OR PREVENTION OF A NEUROLOGICAL DISORDER OF THE IMMUNE SYSTEM
US20210100837A1 (en) * 2017-12-14 2021-04-08 The University Of Chicago Treatment of fibrosis with genetically-engineered macrophages
BR112020015052A2 (pt) * 2018-02-09 2020-12-08 Genmab A/S Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
MA54752A (fr) 2019-01-14 2021-11-24 Univ Virginia Patent Foundation Utilisation d'inhibiteurs d'intégrine pour le traitement ou la prévention d'un trouble immunitaire neurologique et/ou d'une lésion du système nerveux
CN114286690A (zh) * 2019-04-23 2022-04-05 赛诺菲 稳定的低粘度抗体配制品及其用途
CN114555118A (zh) * 2019-08-15 2022-05-27 健玛保 包含针对cd3和cd20的双特异性抗体的药物组合物及其用途
JP2023524149A (ja) 2020-05-08 2023-06-08 ジェンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
CA3189883A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
BR112023004327A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar leucemia linfocítica crônica em um sujeito humano
MX2023002545A (es) 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes.
BR112023004351A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma folicular em um sujeito humano
US20230355753A1 (en) 2020-09-10 2023-11-09 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN117615788A (zh) * 2021-05-12 2024-02-27 安奈普泰斯生物有限公司 抗体组合物

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE150319T1 (de) 1992-01-13 1997-04-15 Biogen Inc Behandlung von asthma
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
DK0682529T4 (da) 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US6111598A (en) 1993-11-12 2000-08-29 Peveo, Inc. System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2182013C (en) 1994-01-25 2007-07-17 Mary M. Bendig Humanized antibodies against leukocyte adhesion molecule vla-4
ATE195428T1 (de) 1994-04-26 2000-09-15 Kanebo Ltd Arznei für rheumatoide arthritis
JPH08131185A (ja) 1994-11-14 1996-05-28 Sumitomo Electric Ind Ltd マウスｖｌａ−１分子に対するモノクローナル抗体
JPH08160972A (ja) 1994-12-01 1996-06-21 Sega Enterp Ltd エフェクト制御方法、制御装置およびこれを利用したカラオケ装置
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9516399D0 (en) 1995-08-10 1995-10-11 Camelot Superabsorbents Ltd Process for the production of water-absorbing compositions
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
AU718138B2 (en) 1995-08-29 2000-04-06 Kyowa Hakko Kirin Co., Ltd. Chimeric animal and method for constructing the same
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6127524A (en) 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ES2190087T3 (es) * 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
CN1187084C (zh) 1998-05-22 2005-02-02 博伊斯镇国家研究医院 α1β1整合蛋白受体抑制剂和TGF－β1抑制剂制备用于治疗肾病的药物组合物的用途
DE19831710A1 (de) 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
WO2000020459A1 (en) 1998-10-06 2000-04-13 Biogen, Inc. Crystals of the alpha 1 beta 1 integrin i-domain and their use
KR100746522B1 (ko) 1999-04-22 2007-08-07 바이오겐 아이덱 엠에이 인코포레이티드 인테그린 알파-4 서브유닛의 길항 물질을 사용하는섬유증의 치료 방법
JP4817503B2 (ja) 1999-06-01 2011-11-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
EP1408839A1 (de) 1999-06-17 2004-04-21 Kai Dr. Desinger Chirurgische sonde zur minimal invasiven gewebeentnahme
AU4259901A (en) 2000-03-28 2001-10-08 Cambridge University Technical Services Limited Receptor/peptide crystal structure for identification of inhibitors
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
EE200300509A (et) 2001-04-13 2004-08-16 Biogen, Inc. Antikehad VLA-1 vastu
EP1441589B1 (en) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
WO2003068262A1 (en) 2002-02-14 2003-08-21 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
EP1546203B1 (en) 2002-08-01 2012-06-20 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
AU2004207003A1 (en) 2003-01-30 2004-08-12 Medimmune, Llc Anti-integrin alphanubeta3 antibody formulations and uses thereof
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
WO2005019177A1 (en) 2003-08-14 2005-03-03 Icos Corporation Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
WO2005019200A2 (en) 2003-08-14 2005-03-03 Icos Corporation Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
US7626243B2 (en) 2006-08-04 2009-12-01 Advanced Analogic Technologies, Inc. ESD protection for bipolar-CMOS-DMOS integrated circuit devices
TR201820837T4 (tr) * 2007-06-14 2019-01-21 Biogen Ma Inc Natalizumab antikor formülasyonları.
JP4951596B2 (ja) 2008-07-31 2012-06-13 株式会社日立製作所 冷却システム及び電子装置
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
CN102770158B (zh) 2009-12-21 2016-10-19 霍夫曼-拉罗奇有限公司 抗体配制剂
KR101853981B1 (ko) * 2010-03-01 2018-05-02 사이토딘 인크. 농축 단백질 제형물 및 그의 용도
KR20130086144A (ko) * 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
JP2014505703A (ja) 2011-02-03 2014-03-06 サンタラス， インコーポレイテッド 対象の選択および治療
WO2013105161A1 (ja) 2012-01-11 2013-07-18 パナソニック株式会社 圧接型半導体装置及びその製造方法
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations

Also Published As

Publication number Publication date
CA2864539A1 (en) 2013-08-22
US10316095B2 (en) 2019-06-11
JP2015508774A (ja) 2015-03-23
JP6759276B2 (ja) 2020-09-23
AU2017265049A1 (en) 2017-12-14
US20140010827A1 (en) 2014-01-09
EP2814468B1 (en) 2019-06-19
CN104271122A (zh) 2015-01-07
EP2814468A2 (en) 2014-12-24
IL233976B (en) 2018-08-30
US20190338036A1 (en) 2019-11-07
HK1199620A1 (en) 2015-07-10
AU2013221635B2 (en) 2017-12-07
MX2014009755A (es) 2015-02-24
AU2017265049B2 (en) 2019-10-24
WO2013123114A2 (en) 2013-08-22
JP6345123B2 (ja) 2018-06-20
US20190194331A1 (en) 2019-06-27
CA2864539C (en) 2022-06-07
AU2013221635A1 (en) 2014-09-18
AU2013221635A2 (en) 2014-12-11
ES2732243T3 (es) 2019-11-21
WO2013123114A3 (en) 2013-12-05
MX370199B (es) 2019-12-05
US20130216556A1 (en) 2013-08-22
US20160017043A1 (en) 2016-01-21
US10160808B2 (en) 2018-12-25
IL233976A0 (en) 2014-09-30
JP2018138614A (ja) 2018-09-06

Similar Documents

Publication Publication Date Title
NZ629204A (en) Anti-vla1 (cd49a) antibody pharmaceutical compositions
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
AR085155A1 (es) Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos
AU2013334740A8 (en) Stable, low viscosity antibody formulation
UA104134C2 (ru) Жидкая композиция, содержащая антитело высокой концентрации
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
CY1118601T1 (el) Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
NZ630885A (en) Antibody formulation
EA201791717A1 (ru) Стабильные водные составы адалимумаба
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
EA201492021A1 (ru) Антительный состав
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MY166045A (en) Abeta antibody formulation
PE20141151A1 (es) Proteinas de union al antigeno cd27l
EA201291168A1 (ru) Фармацевтические композиции и способы их получения
CO6382125A2 (es) Inhibidores de proteína quinasa
PH12014500257A1 (en) Inhibitors of influenza viruses replication
EA201201193A1 (ru) Тиенопиримидины, содержащие гетероциклоалкил, предназначенные для фармацевтических композиций
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
EA201270216A1 (ru) Фармацевтический состав
EA201390467A1 (ru) Композиции антител и способы применения
UA111357C2 (uk) Аналоги епоксіейкозатриєнової кислоти, композиція на їх основі, застосування для лікування захворювань та спосіб зниження гіпертонії та нефротоксичності (варіанти)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 FEB 2018 BY CULLENS PTY LTD

Effective date: 20170608

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 FEB 2019 BY THOMSON REUTERS

Effective date: 20180112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 FEB 2020 BY THOMSON REUTERS

Effective date: 20190119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 FEB 2021 BY THOMSON REUTERS

Effective date: 20200116

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 FEB 2022 BY THOMSON REUTERS

Effective date: 20210112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 FEB 2023 BY ANAQUA SERVICES

Effective date: 20220119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 FEB 2024 BY ANAQUA SERVICES

Effective date: 20230120

LAPS Patent lapsed